Article
Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.
Scientific reports - 19 Apr 2024
Yang Tao, Ke Hang, Liu Jinping, An Xiaoyu, Xue Jia, Ning Jinying, Hao Feng, Xiong Lingxin, Chen Cen, Wang Yueying, Zheng Jia, Gao Bing, Bao Zhengzheng, Gong Kefeng, Zhang Lei, Zhang Faming, Guo Sheng, Li Qi-Xiang
Abstract excerpt
CSF1R is a receptor tyrosine kinase responsible for the growth/survival/polarization of macrophages and overexpressed in some AML patients. We hypothesized that a novel multi-kinase inhibitor (TKi), narazaciclib (HX301/ON123300), with high potency against CSF1R (IC50 ~ 0.285 nM), would have anti-AML effects. We tested this by confirming HX301's high potency against CSF1R (IC50 ~ 0.285 nM), as well as other...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.